Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2026)

Amylyx Pharmaceuticals has reported Non Operating Income for 6 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Non Operating Income rose 60.54% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $10.1 million, a 15.08% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, down 31.7% from the prior year.
• Non Operating Income was $2.3 million for Q2 2026 at Amylyx Pharmaceuticals, down from $2.5 million in the prior quarter.
• The five-year high for Non Operating Income was $4.5 million in Q4 2023, with the low at $112000.0 in Q1 2022.
• Average Non Operating Income over 5 years is $2.5 million, with a median of $2.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 8610.34% in 2022, then sank 60.57% in 2025.
• Over 5 years, Non Operating Income stood at $2.5 million in 2022, then soared by 84.04% to $4.5 million in 2023, then slumped by 45.55% to $2.5 million in 2024, then jumped by 47.67% to $3.7 million in 2025, then tumbled by 37.84% to $2.3 million in 2026.
• The last three Non Operating Income figures came in at $2.3 million (Q2 2026), $2.5 million (Q1 2026), and $3.7 million (Q4 2025), per Business Quant data.